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ABSTRACT
Background: Guidelines and literature debate the importance of testing for bronchial reversibility and its total
significance is unclear. Clinically, patients with greater reversibility have higher fluctuations in respiratory symp-
toms, and hence may have a reduced health-related quality of life (HRQoL). On the other hand, they may have
a better HRQoL as medications may be more effective in this population. Presently, there are no reports con-
cerning the relationship between HRQoL as an indicator of therapy and reversibility. We hypothesized that the
reversibility of airflow limitation might be correlated with the HRQoL in COPD.
Methods: We examined 63 subjects with COPD (mean age: 71.7 years). Reversibility was measured by the
change in FEV1 and FVC after the inhalation of salbutamol (300 μg), and we investigated the relationship be-
tween the reversibility and the parameters of HRQoL, which included St. George’s Respiratory Questionnaire
(SGRQ), Visual analogue scale-8 (VAS-8), Short-Form 36-Item Health Study, Basic activities of daily living, In-
strumental activities of daily living, and the Oxygen cost diagram.
Results: Post-bronchodilator FEV1, % predicted was positively correlated with both the total scores of SGRQ
and VAS-8 (p < 0.0001 and p < 0.006, respectively). Furthermore, the reversibility of FVC was positively corre-
lated with all items of the SGRQ, except for impact (total score: p < 0.02; symptoms: p < 0.02; activity, p < 0.05;
total score of VAS-8: p < 0.02). However, the reversibility of FEV1 was neither correlated with the total score
nor any items in the scales.
Conclusions: Those who have FVC that respond to bronchodilator at rest might result in an improvement of
HRQoL after treatment.
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INTRODUCTION
The role of bronchodilator reversibility (BDR) in
chronic obstructive pulmonary disease (COPD) is im-
portant in establishing a diagnosis and determining
therapeutic strategies.1-3 According to recent ATS
ERS guidelines,2 the objectives for bronchodilator re-
versibility tests are as follows: exclusion of bronchial
asthma in the diagnosis of COPD, measurements of
the best and highest values for the pulmonary func-
tion test, prediction of the outcome, and determina-
tion of therapeutic strategies. However, the efficacy
of long-acting bronchodilators cannot be predicted
from that of short-acting bronchodilators.1-3 The sig-
nificance of BDR on outcomes is ill-defined. HRQOL
is one measure of outcomes in COPD patients. Clini-
cally, patients with greater reversibility have higher
fluctuations in respiratory symptoms, which may ad-
versely affect their health-related quality of life
(HRQoL). On the other hand, the benefit from medi-
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cines may be greater in patients with a higher BDR,
resulting in an improved HRQoL. To our knowledge,
no previous study concerning the relationship be-
tween HRQoL as an indicator of therapy and bron-
chial reversibility has been reported.
Standard guideline consensus for bronchodilator
reversibility has not yet been obtained. Two major is-
sues are likely warranted in this regard. First, a stan-
dard calculation formula has not been determined,4-6
and second, the clinical indications or applications for
reversibility data need to be clarified. The response to
inhaled bronchodilators can be assumed by measur-
ing lung functions, usually FEV1, before and after
drug administration.1-3 This may be a useful test;
however, it should not be used as an absolute guide
for the administration of a bronchodilator since the
response to bronchodilators on a particular occasion
may not accurately reflect responses at other times.7
Moreover, there is no consensus as to what consti-
tutes a significant response to bronchodilator ther-
apy, with any cut-off point being arbitrary in COPD.8
Substantial evidence suggests that ‘reversibility’ is a
continuous variable rather than a dichotomous trait.9
However, since forced vital capacity (FVC), slow vital
capacity (SVC), inspiratory capacity (IC), and exer-
cise tests show better correlations with symptoms in
COPD,10-13 there is good reason to measure response
rather than FEV1 in such patients. In the present
study, we hypothesized that reversibility of airflow
limitations might be correlated with the health-
related quality of life in COPD.
METHODS
The subjects were 63 consecutive patients who in-
itially consulted the outpatient clinic at the Respira-
tory Care Clinic, Nippon Medical School, Tokyo, Ja-
pan, for ambulatory treatment. Eligible patients ful-
filled the following criteria: 1) patients whose clinical
course, clinical symptoms, and laboratory data satis-
fied criteria for the clinical diagnosis of COPD,1 and
2) those with a life-long history of smoking, including
current and ex-smokers.
We excluded those:
1) with a history of atopy, or those with any appar-
ent asthmatic features
2) receiving any corticosteroid regimens
3) with exacerbations during the preceding three
months
4) with cognitive disorders, as assessed using the
mini-mental state examination (MMSE),14 with a
score less than 26
5) with other respiratory diseases such as bron-
chiectasis or any pulmonary fibrosis or cardiac disor-
ders
This study was approved by the Ethics Committee
of the institute, and the subjects were enrolled after
appropriate informed consent was obtained.
LUNG FUNCTION TESTS AND REVERSIBILITY
OF AIRFLOW LIMITATIONS
Patients were told to abstain from bronchodilators
(BD), including any types of β2 agonists andor anti-
cholinergic regimen, for 12 hours before testing.
There were no cases that received tiotropium at this
stage. Spirometry was performed before, then 20
minutes after an administration of 300 μg of salbuta-
mol (Glaxo Smith Kline, UK), using a meter-dose in-
haler with an inhalation chamber (715 ml). The best
record of three measurements was used for the analy-
sis. FVC was measured via forced expiration for at
least six seconds. In cases of older participants, ap-
propriate attention was paid to the technique as de-
scribed previously.15 The reversibility by salbutamol
inhalation was calculated for both FEV1 and FVC, in
addition to the air trapping index. The reversibility of
FEV1 was calculated by the following formula:16
([post-BD FEV1 − pre-BD FEV1]pre-BD FEV1)×
100%.
The reversibility of FVC was similarly defined. The
air trapping index was calculated using the following
equation: (VC-FVC) × 100VC.
QUALITY OF LIFE AND ACTIVITIES OF DAILY
LIVING
All of the patients were measured for a generic and
health-related quality of life (HRQoL) on the same
day that the lung function test was performed. These
included St George’s Respiratory Questionnaire
(SGRQ),17 Short-Form 36-Item Health Study (SF-
36),18,19 and the Visual analogue scale-8 quality of life
(VAS-8 QOL).20,21 Activities of daily living (ADL)
were evaluated using items from the basic activities
of daily living (BADL)22 and the instrumental activity
of daily life (IADL),23 while dyspnea on exertion was
evaluated using items from the oxygen cost diagram
(OCD).24 Japanese versions of SGRQ and OCD were
used in this study.25,26
To assess exercise capacity, the six-minute walking
distance test (6MWD) was applied using the standard
protocol.27
OTHER CLINICAL TESTING
Arterial blood gas was simultaneously measured
while room air was breathed in a supine position. To
exclude co-morbidity including heart failure, chest X-
ray (posterior-anterior direction), ECG, and blood
chemistry were performed.
STATISTICS
All results are expressed as means ± SEM. Group
means were compared by analysis of variance
(ANOVA) followed by a multiple comparison of
means by Fisher’s least-significance procedure. All
statistical tests were two-tailed and p < 0.05 was con-
sidered significant. To investigate the relationship be-
tween reversibility and HRQoL, linear regression
Airway Reversibility in COPD
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Table 1 Patient characteristics.
Male (n＝56), Female (n＝7)n (n＝63)
(72.0 ± 0.9/69.4 ± 0.9)71.7 ± 0.9 (70.0―73.4)Age (yr) (M/F)
DiferencePost-bronchodilatorPre-bronchodilator
0.24 ± 0.03 (0.18―0.30)2.66 ± 0.08 (2.51―2.81)2.42 ± 0.08 (2.26―2.58)FVC
0.10 ± 0.02 (0.07―0.13)1.38 ± 0.07 (1.38―1.51)1.28 ± 0.07 (1.15―1.41)FEV1
 － 0.53 ± 0.57 (－ 1.67―0.60)51.4 ± 1.68 (48.0―54.7)51.9 ± 1.55 (48.8―55.0)FEV1/FVC
4.08 ± 0.63 (2.81―5.34)55.7 ± 2.70 (50.3―61.1)51.6 ± 2.65 (46.3―56.9)FEV1, %predict
Arterial blood gas
(7.41―7.43) 7.42 ± 0.004pH
(41.6―43.9)42.8 ± 0.58PaCO2 (mmHg)
(72.1―76.9)74.5 ± 1.19PaO2 (mmHg)
(386.9―443.9)415.4 ± 14.1 6MD (m)
ADL
(19.9―20.0)20.0 ± 0.03BADL
(25.5―27.2)26.4 ± 0.42IADL
(75.4―85.1)80.3 ± 2.45OCD
SF-36
(65.4―76.4)70.9 ± 2.76Physical-function
(47.6―69.6)58.6 ± 5.51Role-physical
(69.3―81.2)75.2 ± 2.98Body-pain
(45.2―56.5)50.9 ± 2.84General health
(56.9―68.7)62.8 ± 2.95Vitality
(75.3―87.4)81.4 ± 3.00Social
(39.6―66.4)53.0 ± 6.72Role-emotional
(63.2―75.2)69.2 ± 3.00Mental health
(42.6―47.1)44.8 ± 1.14PCS
(44.2―49.9)47.1 ± 1.44MCS
Definition of abbreviations: 6MD = six-minute walking distance test; ADL = Activities of daily living; BADL: Basic activities of daily liv-
ing; IADL = Instrumental activities of daily living; 6MD = six-minute walking distance test; OCD = Oxygen cost diagram; SF-36 = Short-
Form 36-Item Health Study; PCS = Physical Cornel Summary; MCS = Mental Cornel Summary.
Table 2 Corelation between post-bronchodilator FEV1, 
% predicted and the health-related quality of life.
SGRQ
r2＝0.300p＜0.0001Total SGRQ score
r2＝0.119p＜0.0007Symptoms
r2＝0.338p＜0.0001Activity
r2＝0.169p＜0.0006Impact
VAS-8 QOL
r2＝0.239p＜0.006Total
r2＝0.143p＜0.04Dyspnea
r2＝0.118p＜0.05Social activity
r2＝0.188p＜0.002Housework or job
r2＝0.121p＜0.01Appetite
r2＝0.145p＜0.005Anxiety
Definition of abbreviations: SGRQ = St George’ s Respira-
tory Questionnaire; VAS-8 QOL = Visual analogue scale-8 
quality of life.
analysis was applied, taking the Pearson correlation
coefficient as a measure of the extent of the relation-
ship. Calculations for statistical analysis were per-
formed using SPSS 11.0 (SPSS Inc.; Illinois, 2001).
RESULTS
Participant characteristics are shown in Table 1. A to-
tal of 63 subjects, consisting of 56 men and 7 women,
with a mean age of 71.7 years, were studied; there
were no significant differences in age between men
and women. Mean values of reversibility in FEV1
(∆FEV1) and FVC (∆FVC) were 9.6% and 11.4%, re-
spectively. Post-bronchodilator FEV1, % predicted
was positively correlated with the following items of
SGRQ: total score (p < 0.0001, r2 = 0.300), symptoms
(p < 0.0007, r2 = 0.119), activity (p < 0.0001, r2 =
0.338), and impact (p < 0.0006, r2 = 0.169) (Table 2).
In addition, post-BD FEV1, % predicted was positively
correlated with the following items of VAS-8QOL: to-
tal score (p < 0.006, r2 = 0.239), dyspnea (p < 0.04, r2 =
Omata M et al.
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Fig. 1 Relationship between the reversibility of forced vital capacity and St. Georges’s 
Respiratory Questionnaire. ΔFVC was positively corelated with al SGRQ items except for 
impact.
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0.143), social activity (p < 0.05, r2 = 0.118), housework
or job (p < 0.002, r2 = 0.188), appetite (p < 0.01, r2 =
0.121), and anxiety (p < 0.005, r2 = 0.145) (Table 2).
However, neither the volume nor the percentage of
FEV1 reversibility was positively correlated with any
item of SGRQ, VAS-8 QOL, or SF-36, nor with BADL,
or IADL.
Figure 1 shows the relationship between ∆FVC and
SGRQ items. ∆FVC was positively correlated with all
SGRQ items except for impact (total score, p < 0.02,
r2 = 0.098; symptoms, p < 0.02, r2 = 0.068; activity, p <
0.05, r2 = 0.087).
Figure 2 indicates the relationship between the re-
versibility of FVC (∆FVC) and VAS-8 QOL items.
∆FVC was positively correlated with the following
items of VAS-8 QOL: total score (p < 0.02, r2 = 0.100),
dyspnea (p < 0.002, r2 = 0.177), social activities (p <
0.05, r2 = 0.072), and headache (p < 0.04, r2 = 0.079).
∆FVC was correlated with OCD (p < 0.002, r2 =
0.159), the social functioning of SF-36 (p < 0.02, r2 =
0.101), and the air trapping index (p < 0.005, r2 =
0.128) (Table 3). However, ∆FVC was not correlated
with either BADL or IADL. Although the air trapping
index was not correlated with ∆FEV1, it was posi-
tively correlated with ∆FVC (p < 0.005, r2 = 0.128).
The air trapping index was not correlated with any
item of VAS-8QOL; however, it was positively corre-
lated with the following items of SGRQ: total score
(p < 0.006, r2 = 0.118), symptoms (p < 0.05, r2 = 0.066),
activity (p < 0.03, r2 = 0.083), and impact (p < 0.02, r2 =
0.094). For SF-36, it was positively correlated with
body pain (p < 0.006, r2 = 0.124) and the physical com-
ponent summary (PCS) (p < 0.04, r2 = 0.070).
There was no correlation between ∆FVC and the
six-minute walking distance test (6MWD), and no
correlation between reversibility in FEV1 and the
6MWD was observed.
DISCUSSION
The present study investigated bronchodilator re-
Airway Reversibility in COPD
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Fig. 2 Relationship between the reversibility of forced vital capacity and visual analogue 
scale-8 QOL. Reversibility of FVC was positively corelated with the folowing items of VAS-
8 QOL: total score (p＜0.02, r2＝0.100), dyspnea (p＜0.002, r2＝0.177), social activities 
(p＜0.05, r2＝0.072), and headache (p＜0.04, r2＝0.079).
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Table 3 Corelation between the reversibility of forced vi-
tal capacity and other factors.
SGRQ
r2＝0.098p＝0.0126Total score
r2＝0.068p＝0.0387Symptoms
r2＝0.087p＝0.0192Activity
VAS-8 QOL
r2＝0.100p＝0.0188Total score
r2＝0.177p＝0.0014Dyspnea
r2＝0.072p＝0.0469Social activity
r2＝0.079p＝0.0371Headache
r2＝0.159p＝0.0012OCD
SF-36
r2＝0.101p＝0.0124Social functioning
r2＝0.128p＝0.0040Air trapping index
Definition of abbreviations: SGRQ = St George’ s Respira-
tory Questionnaire: VAS-8 QOL = Visual analogue scale-8 
quality of life; OCD = Oxygen cost diagram; SF-36 = Short-
Form 36-Item Health Study
versibility in stable COPD, and reported a cross-
sectional relationship between bronchodilator re-
versibility and the respective items of the health-
related QOL and activities of daily living.
The present study showed several interesting find-
ings. ∆FVC was positively correlated with HRQoL, as
shown in Figure 1 and 2. The air trapping index was
significantly and positively correlated with ∆FVC, and
also with many items in the HRQoL.
Newton et al. reported that a relatively low dose of
inhaled salbutamol reduces hyperinflation and gas
trapping in patients with significant baseline hyperin-
flation, often to a remarkable degree, even in patients
with advanced disease.28 Figure 3 shows the detailed
correlations among HRQOL items, ∆FVC, ∆FEV1,
and the air trapping index. Items showing a correla-
tion are represented by circles, while those without a
correlation are represented by ×. It is possible that
these reflect an improvement in pulmonary hyperin-
flation. According to the present results, air trapping
Omata M et al.
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Fig. 3 Possible relationship between QOL and pulmonary 
function. Detailed corelations among HRQoL items, ΔFVC 
(the reversibility of FVC), ΔFEV1 (the reversibility of FEV1), 
and the air trapping index. Items showing a corelation are 
represented by ○, while those without a corelation are rep
resented by ×. 
ΔFVC
HRQoL
Air trapping
index
ΔFEV1
in COPD might be the contributing factor for the de-
crease in HRQoL. The improvement of FVC might
suggest the improvement of air trapping, and may re-
flect the significant correlation between the reversi-
bility of FVC and HRQoL.
However, several points in the study design, which
might have influenced the results, should be pointed
out. First, the subjects involved in this study were
limited to patients with stable COPD. In addition,
more than 90% of the subjects were 65 years old or
older. Previous studies have demonstrated that the
level of salbutamol-induced bronchodilator response
decreases with age, although the level of ipratropium-
induced bronchodilator response is not influenced by
age.29,30 However, Nisar and associate report31 that
the influence of age on the bronchodilator response
is limited, and suggest that this may reflect the pro-
gression of the disease rather than an age-related dif-
ference in the number of receptors.
Second, the dose of salbutamol was fixed in this
study. Previous reports32,33 suggest that the inhala-
tion of salbutamol at a dose higher than 300 μg facili-
tated the differentiation of asthmatic patients from
chronic bronchitic patients. Moreover, most data
from the dose-response by salbutamol in COPD pa-
tients suggest that the inhalation of 800 μg of salbuta-
mol induces a maximal or near maximal response.34
Since the subjects in our study were shifted towards
the elderly (mean age: 71.7 years), 300 μg of salbuta-
mol was inhaled to avoid the occurrence of adverse
effects on the cardiovascular system with the per-
spective of application in daily clinical practice.
Third, we used the pre-bronchodilator value of
FEV1, which was conventional, to evaluate the re-
versibility of FEV1. This tends to show that patients
with severe COPD will exhibit stronger bronchodila-
tor responses.35
When a formula is used that divides the predicted
value of FEV1, which was proposed by Anthonisen et
al.4 and Eliasson et al.,33 it suggests that expressing
the results of reversibility tests as the degree of vari-
ation does not produce mathematical biases. Further-
more, it is speculated that the degree of variation of
reversibility is influenced by physical characteristics
such as gender, age, and height, or a previous clinical
course such as acute exacerbations, where the pa-
tient might be receiving systemic corticosteroid.
There is substantial debate about the most appropri-
ate method of calculating the reversibility of FEV1.4-6
Fourth, inspiratory capacity (IC) measured by
plethysmography might be required to determine re-
versibility more precisely. Using absolute or percent-
age changes in FEV1 might underestimate bron-
chodilator reversibility in COPD. Two reasons for
this are that 1) dynamic airway collapse occurs dur-
ing forced expiration, and 2) it is likely that many
more subjects with COPD would have had a signifi-
cant BDR if slow and unforced vital capacity maneu-
vers had been used.35,36
In this study, we did not measure the response of
IC before and after salbutamol inhalation, because
the present study aimed to clarify the significance of
routine clinical application by spirometry use (based
on FVC with forced expiration over at least six sec-
onds).
O’Donnell et al.37 performed spirometry and
constant-volume body plethysmography. Despite its
disadvantages, spirometry is easy to perform and is
widely used in routine clinical settings. On the other
hand, during body plethysmography, it is important
to maintain oral and alveolar pressures at an equal
level, though this is not always possible. In particular,
it might be hard to maintain the quality of pressure in
patients with airway obstruction. In such cases,
higher values for the intrathoracic gas volume can be
obtained by dynamic changes in the upper airway
when panting is performed under the condition of in-
creased airway resistance. It is a likely disadvantage
that this error increases with the severity of airway
obstruction.38 However, reversibility using body
plethysmography should be conducted in the future
for further evaluation.
According to Newton et al.,28 regardless of whether
the choice for a volume response is governed by the
convenience of using a spirometric index such as
FVC or by the intent of maximizing the effect by add-
ing IC and RV, the volume effects are relatively simi-
lar after bronchodilator administration.
The measurement of FVC in COPD patients re-
mains controversial. ATS statements in 1991 sug-
gested that the total expiration time should be consid-
ered for evaluating FVC as a bronchodilator re-
sponse, as patients with obstructive pulmonary dis-
ease show a prolonged expiration time and increased
FVC.39 Thus, we adopted a forced expiration for over
Airway Reversibility in COPD
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six seconds for measuring FVC. In their study, Wil-
liam et al. reported40 that the response after increases
in FEV3 and FEV6 may be a secure bronchodilator
response, and that the significance of a response oc-
curring after the increase in FVC alone remains un-
clear, as this increase in FVC is due to the prolonged
expiration time. Considering the results of the study
reported by William et al.,40 it is preferable to use
FEV6 as an index instead of FVC for bronchodilator
response in the future.
It has been reported that changes in FEV1 after the
inhalation of β2-agonists in COPD patients were not
associated with an improvement in the perception of
dyspnea.10,12,41 Changes in FEV1 were limited to a
narrow range whereas the reversibility of FVC was
widely distributed. These findings support a notion
that a better health-related QOL can be obtained in
COPD patients by exhaling as much breath as possi-
ble during expiration. The present study suggests
that the bronchodilator-induced reversibility of FVC
is associated with HRQoL. This was supported by the
findings that ∆FVC was positively correlated with SF-
36 and changes in OCD as well as SGRQ and VAS-8
QOL. Since our study population was small, the pre-
sent findings need to be further evaluated in a larger
patient population.
As summarized in Figure 3, there was a correlation
between the reversibility in FEV1 and in FVC; how-
ever, no correlation was noted between the air trap-
ping index and the reversibility in FEV1. As COPD
progressed, destruction of both supporting tissue and
elastic fibers in the lung result in reduced recoil and
tethering, which increased airway resistance and ex-
piratory flow limitation. In patients with COPD, inha-
lation of the short-acting β-agonist, salbutamol, re-
duce symptoms without improving the FEV110,12
which suggest that the airway diameter in resting res-
piration may be improved, or functional residual ca-
pacity (FRC) may decrease the work to be done by
inspiratory muscles. The distance achieved after
walking for 6 minutes increased after bronchodilator
administration, and this may have been attributed to
an improvement of FVC, rather than FEV1. Since an
increase in FVC decreases resting FRC, which may
reduce the range of dynamic hyperinflation during
exercise.28 More recently, O’Donnell el al.42 reported
that inhalation of a long-acting cholinergic regimen
resulted in consistent improvements in trough FEV1
compared to a placebo, with little or no change in the
FEV1FVC ratio. They observed that the slight
changes in FEV1 mainly reflect the increase in FVC.
An increased vital capacity (VC) is inversely related
to decreased residual volume (RV), which occurs as
result of complete lung emptying. Improvement of
dyspnea on exertion in COPD after inhalation of the
regimen was attributed to a decrease in RV and an in-
crease in inspiratory capacity (IC) rather than an im-
provement of FEV1; thus, they concluded that the ef-
fect is due to an improvement of dynamic hyperinfla-
tion. Although these results support the notion, the
precise reason why no correlation was observed be-
tween the air trapping index and reversibility in FEV1
in this study remains to be clarified, and requires fur-
ther study.
Since the spirogram suggested that FVC was
FEV6,40 FEV1 reversibility may be correlated with
FVC reversibility.
Our results from the reversibility tests for airway
obstruction for both FEV1 and FVC are likely to pro-
vide useful information. In addition, the measurement
of reversibility in FVC may become a useful clinical
marker in terms of HRQoL. This supports the useful-
ness of pursed-lip expiration and bronchodilators for
COPD treatment.43
In conclusion, the improvement of FVC by β-
agonist inhalation might be closely correlated with
the health-related quality of life; thus, this measure-
ment might provide different clinical information
from the reversibility of FEV1.
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